醫療新知 > 癌細胞清除乾淨沒 這枝筆輕輕一掃便知

癌細胞清除乾淨沒 這枝筆輕輕一掃便知




法新社報導,美國德州大學奧斯汀分校(University of Texas at Austin)科學家和工程師研發的這項工具稱為「質譜筆」(MasSpec Pen,暫譯),能讓移除腫瘤的外科醫師在幾秒內就能偵測出組織裡的癌細胞,讓醫師立刻知道自己是否已經發現且移除所有癌細胞。


美聯社引述研究主筆、德州大學奧斯汀分校化學副教授厄伯林(Livia Eberlin)表示,每個人最大夢魘,莫過於動刀後仍有癌細胞殘留的可能性,「透過提供即時分子資料,我們真的可以提高精準度」。

「科學轉譯醫學」(Science Translational Medicine)今天刊登的研究指出,這種筆在手術中只需10秒左右的時間就能辨識出癌組織。










The MasSpec Pen is a handheld probe that can non-destructively analyze human tissue samples to identify cancer. Vivian Abagiu/Univ. of Texas at Austin

This Pen Can Diagnose Cancer in 10 Seconds

Sep 06, 2017

TIME Health

For more, visit TIME Health.

When it comes to treating cancer, surgeons want to get rid of as much cancerous tissue as possible during tumor removal. Now a new technology—the size of a pen—is attempting to make that easier by distinguishing between tumors and healthy tissue in just 10 seconds.

The MasSpec Pen is a real-time diagnostic tool created by researchers at the University of Texas at Austin. In a new study published Wednesday in the journal Science Translational Medicine, the researchers report that their handheld device (which is not yet FDA-approved) uses tiny droplets of water to analyze human tissue samples for cancer with 96% accuracy.


“It’s a gentle, simple chemical process,” says study author Livia Schiavinato Eberlin , an assistant professor of chemistry at UT Austin. “It’s highly specific and highly sensitive. The fact that it’s non-destructive brings a new approach to cancer diagnosis.”

MORE: Researchers Find a Way to Light Up Cancer Cells

Getting rid of all cancerous tissue while also preventing any harm to healthy tissue is a delicate process. When operating on a woman with breast cancer, for example, a doctor needs to remove the tumor and other affected tissues while maintaining the rest of the breast. Currently there are other tools available to surgeons for tissue diagnosis, but many use gases or solvents that can be harmful for the human body. In 2016, researchers in Massachusetts reportedthat they developed a probe that can find and light up cancer cells, making them easier for surgeons to see. But other methods currently available to surgeons today are slower than the MasSpec Pen, the study authors say, in some cases by 30 minutes or more.

Human cells produce a variety of small molecules, and cancer creates a unique set of them that can be used for pattern identification. The MasSpec Pen produces a small drop of water that extracts molecules from a person’s cells during surgery. Through machine learning, the MasSpec Pen is able to determine what molecular fingerprint is normal and what is cancer, Eberlin says.

In the study, the researchers tested 253 human tissue samples from lung, ovary, thyroid and breast cancer tumors and compared them to samples of healthy tissues. The device was 96% accurate at identifying cancerous tissues. The researchers also tested the MasSpec Pen in live mice with tumors and found that the device was able to identify the presence of cancer without harming healthy surrounding tissues. The device can also identify different subtypes of lung and thyroid cancer, and the team hopes to make it more specified for other types of cancer, too.


The researchers say they need to continue validating their work and that they plan to start clinical testing in humans in 2018. Until then, it’s unclear how exactly the device will work when integrated into surgery. While the pen-sized device that the surgeon would use is small, the device is connected to a large mass spectrometer, which helps the process of analyzing individual molecules . That large machine would need to be wheeled in and out of a surgery room for each procedure. The pen is disposable, so surgeons would replace it with each surgery.

“This is a good example of a tool that empowers our transition to precision medicine where the treatment can be done with much higher levels of confidence,” says study author Thomas Milner, professor of biomedical engineering in UT Austin's Cockrell School of Engineering . “Treatment can be planned and given where the outcomes are known. This is one tool along that path.”




慢性淋巴細胞白血病 (CLL) 口服標靶藥 助病人長時間穩定病情
王紹明醫生 中文大學內科及藥物治療學系名譽臨床副教授 「慢性淋巴細胞白血病 (Chronic lymphocy […]
中大全球首證血糖波動不穩的肥胖型糖尿病患者有較高患癌風險 並證實接受一類常用降血壓藥物的糖尿病患者患癌風險則較低
香港中文大學(中大)醫學院利用大數據研究糖尿病患者的患癌風險,首次獲得兩項重要發現。研究團隊發現患有糖尿病並有 […]
抗癌治療的副作用為患者帶來巨大的生理和心理壓力,肝膽胰癌症患者更經常因器官受損,比其他癌症患者較易出現相關副作 […]
中大與國際團隊領導肺癌研究 證實Lorlatinib可成為ALK陽性晚期非小細胞肺癌一線治療
香港中文大學(中大)醫學院莫樹錦教授與國際肺癌專家團隊早前針對帶有「間變性淋巴瘤激酶(ALK)基因變異」的晚期 […]
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌
中大研發嶄新治療組合 帶領亞洲策略性抗擊膽管癌 2022年8月8日 1 中大醫學院領導的一項多中心臨床研究發現 […]
新藥Dostarlimab給MMR缺損病人的新希望 [醫療新資訊] MMR缺損對人們有甚麼影響呢﹖為甚麼新藥D […]
【創新科研】中大研新型抗癌免疫療法及可彎曲手術鑽 全國挑戰杯共奪5獎
【創新科研】中大研新型抗癌免疫療法及可彎曲手術鑽 全國挑戰杯共奪5獎 ▲ 左起:病理解剖及細胞學系助理教授鄧銘 […]
芯片上的蠕蟲能視作癌症偵察器﹖ [癌症資訊新聞] 根據《科學報告》學術期刊發表了一篇研究報告指,科學家利用秀麗 […]
基石藥業胃腸道間質瘤精準靶向藥(avapritinib)在香港正式上市 創新療法有望惠及更多患者
基石藥業胃腸道間質瘤精準靶向藥(avapritinib)在香港正式上市 創新療法有望惠及更多患者   在眾多癌 […]